Cytopia targeting protein kinases
Wednesday, 18 June, 2008
Melbourne biotech Cytopia (ASX: CYT) is to present data from its study on FMS inhibitors at the Protein Kinase Targets oncology conference in Boston next week.
This will be the first formal disclosure of data from the study, in which a series of compounds discovered by Cytopia were found to inhibit the function of microphages, key cells in the immune system which also mediate inflammatory reactions.
One of the potential applications of the compounds is as a treatment of rheumatoid arthritis. The compounds are also showing potential as an inhibitor of the cells that cause bone osteolysis in advanced cancer sufferers.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
